Financial Performance - The company's operating revenue for 2024 reached ¥1,475,741,034.67, representing a year-on-year increase of 16.89% compared to ¥1,262,530,882.14 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥354,792,033.04, which is a 22.59% increase from ¥289,419,389.73 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥350,966,371.48, up 34.25% from ¥261,425,250.85 in 2023[23]. - The basic earnings per share for 2024 was ¥0.89, reflecting a 25.35% increase from ¥0.71 in 2023[24]. - The total assets of the company as of the end of 2024 were ¥3,877,422,385.61, a significant increase of 50.60% from ¥2,574,610,570.52 in 2023[23]. - The weighted average return on equity for 2024 was 17.35%, an increase of 1.26 percentage points from 16.09% in 2023[25]. - The cash flow from operating activities for 2024 was ¥332,405,825.62, down 13.80% from ¥385,605,552.66 in 2023[23]. - The company reported a net profit of ¥82,184,172.26 in Q1 2024, with total revenue of ¥335,623,155.40 for the same period[26]. - The company recorded a net profit of ¥106,407,908.48 in Q2 2024, with revenue of ¥395,033,849.16[26]. - The company achieved a revenue of 1.476 billion yuan in 2024, a year-on-year increase of 16.89%, and a net profit of 355 million yuan, up 22.59% from the previous year[31]. Dividend Policy - The company plans to distribute a cash dividend of RMB 2.90 per 10 shares (including tax), totaling approximately RMB 117,796,550.00, which accounts for 33.20% of the net profit attributable to shareholders for the year 2024[6]. - The company has maintained a consistent cash dividend policy, distributing at least 20% of the distributable profit as cash dividends annually when conditions permit[153][155]. - Over the last three fiscal years, the cumulative cash dividend amount (including tax) was RMB 27,215.07 million, with an average cash dividend payout ratio of 95.47% of the average annual net profit[162]. - The company has not proposed any stock dividends or capital reserve transfers for the 2024 fiscal year, opting to retain undistributed profits for future allocation[156]. - The company’s cash dividend distribution plan for 2024 has been approved by the board and is pending shareholder approval at the annual general meeting[156]. Research and Development - Research and development expenses totaled 146 million yuan, a 6.91% increase year-on-year, with 45 ongoing projects in various drug categories[34]. - The company submitted 29 invention patent applications and received 13 new authorized patents during the reporting period, enhancing its intellectual property portfolio[36]. - The company has established six major engineering technology innovation platforms, enhancing its R&D capabilities[54]. - The company’s R&D investment during the reporting period accounted for 9.92% of its operating revenue, with a net asset ratio of 6.28%[92]. - The company is investing in new product development and technology research to drive innovation and competitiveness in the market[129]. - The company plans to increase R&D expenditure to 143 million yuan in 2024, representing a year-on-year growth of 4.30%[116]. Market Expansion and Strategy - The company is actively expanding its market presence through new product development and regulatory approvals in both domestic and international markets[87]. - The company plans to continue expanding its market share and product offerings in the coming year[66]. - Market expansion plans include entering two new international markets by the end of 2024, aiming for a 30% increase in global sales[130]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million allocated for potential mergers and acquisitions[130]. - The company aims to achieve a revenue growth target of 10% in the next fiscal year, supported by new product launches and market strategies[129]. Environmental Responsibility - The company invested approximately 26.43 million yuan in environmental protection during the reporting period[171]. - The company has implemented various pollution prevention measures, including advanced wastewater and waste gas treatment systems[181][183]. - The company is committed to continuous improvement in environmental management, having obtained ISO 14001:2015 certification for its environmental management system[195]. - The company has established a comprehensive environmental risk emergency mechanism, with the emergency response plan filed with the local environmental authority[187]. - The company has installed online monitoring systems for wastewater and VOCs at discharge points, ensuring compliance with environmental standards[190]. Corporate Governance - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has a structured decision-making process for profit distribution, requiring board approval and submission to the shareholders' meeting[154]. - The company’s management performance evaluation and incentive mechanisms are overseen by the remuneration and assessment committee of the board[166]. - The company held two shareholder meetings during the reporting period: the first extraordinary meeting in January 2024 and the annual meeting in May 2024[126]. - The company has established a structured compensation policy aimed at attracting and retaining talent, with a focus on performance-based evaluations[150]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[9]. - The company has not faced any substantial impact on its production and operations from major risks during the reporting period[9]. - The company faces risks from international trade environment changes, which could impact its export business[112]. - The company is committed to complying with new industry regulations, including "consistency evaluation of generic drug quality and efficacy" and "centralized procurement," to ensure sustainable profitability[118]. - The company faces risks from intensified competition, particularly from developed countries and emerging markets, which may adversely affect performance if competitive advantages are not maintained[117].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 401,995,270.58, representing a 19.78% increase compared to CNY 335,623,155.40 in the same period last year[4] - Net profit attributable to shareholders was CNY 119,417,662.41, a 45.30% increase from CNY 82,184,172.26 year-over-year[4] - The net profit after deducting non-recurring gains and losses was CNY 112,987,049.26, reflecting a 37.51% increase compared to CNY 82,167,819.58 in the previous year[4] - Basic earnings per share increased by 50.00% to CNY 0.30 from CNY 0.20 in the previous year[4] - Diluted earnings per share also rose by 50.00%, reaching CNY 0.30 compared to CNY 0.20 last year[5] - Total operating revenue for Q1 2025 reached ¥401,995,270.58, a 19.7% increase from ¥335,623,155.40 in Q1 2024[18] - Net profit for Q1 2025 was ¥119,417,662.41, representing a 45.3% increase compared to ¥82,184,172.26 in Q1 2024[19] - Basic and diluted earnings per share for Q1 2025 were both ¥0.30, up from ¥0.20 in Q1 2024[20] - The company reported a total profit of ¥141,535,689.38 for Q1 2025, up from ¥99,108,144.14 in Q1 2024[19] Cash Flow - The net cash flow from operating activities decreased by 71.26%, amounting to CNY 25,705,558.93, down from CNY 89,426,909.65 in the same period last year[4] - Operating cash inflow totaled $397,906,535.95, an increase from $384,208,482.52 year-over-year[23] - Operating cash outflow amounted to $372,200,977.02, compared to $294,781,572.87 in the previous period[23] - Net cash flow from operating activities was $25,705,558.93, down from $89,426,909.65 year-over-year[23] - Cash inflow from investment activities reached $269,306,482.21, significantly higher than $539,851.53 in the prior period[23] - Cash outflow from investment activities was $332,502,382.62, compared to $140,559,046.91 previously[23] - Net cash flow from investment activities was -$63,195,900.41, an improvement from -$140,019,195.38 year-over-year[23] - Cash inflow from financing activities totaled $63,127,400.00, down from $134,514,228.46[24] - Cash outflow from financing activities was $60,151,348.75, compared to $102,191,356.54 in the previous period[24] - Net cash flow from financing activities was $2,976,051.25, a decrease from $32,322,871.92 year-over-year[24] - The ending cash and cash equivalents balance was $736,602,666.87, up from $400,661,672.44 in the prior period[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,897,048,240.76, a slight increase of 0.51% from CNY 3,877,422,385.61 at the end of the previous year[5] - The equity attributable to shareholders increased by 4.68% to CNY 2,440,575,900.00 from CNY 2,331,528,721.53 at the end of the previous year[5] - The company's total liabilities decreased to RMB 1,456,472,340.76 from RMB 1,545,893,664.08, reflecting a decrease of approximately 5.8%[14] - Current liabilities decreased to RMB 437,873,952.97 from RMB 532,037,038.75, a reduction of about 17.7%[14] - Non-current assets totaled RMB 1,874,767,784.63, up from RMB 1,830,626,381.82, marking an increase of about 2.4%[13][14] - The company reported a significant increase in fixed assets, which rose to RMB 776,502,004.08 from RMB 606,807,832.86, an increase of approximately 28%[13] - Cash and cash equivalents decreased to RMB 736,602,666.87 from RMB 769,439,830.87, reflecting a decline of approximately 4.8%[12] - Accounts receivable increased to RMB 393,092,250.58 from RMB 349,757,854.06, representing an increase of about 12.4%[13] - Inventory rose to RMB 614,823,371.98 from RMB 589,721,953.58, indicating an increase of approximately 4.3%[13] Non-Recurring Items - Non-recurring gains and losses amounted to CNY 6,430,613.15, with government subsidies contributing CNY 4,178,427.58[6] - Other comprehensive income for Q1 2025 was -¥32,591.37, compared to ¥34,431.97 in Q1 2024[20] Shareholder Information - The company has no significant changes in the top 10 shareholders or their participation in margin trading[11] - There are no new strategies or major product developments mentioned in the conference call[11] Research and Development - Research and development expenses for Q1 2025 were ¥32,087,224.10, compared to ¥28,932,083.97 in Q1 2024, reflecting a 10.4% increase[19]

关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605116 证券简称：奥锐特 公告编号：2025-032 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 重要内容提示： 会议召开时间：2025 年 05 月 08 日（星期四）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.ss einfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 （一）会议召开时间：2025 年 05 月 08 日下午 15:00-16:00 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 04 月 28 日（星期一）至 05 月 07 日（星期三）16:00 前登录上证路演中心网站首页点击"提 ...

奥锐特药业股份有限公司 证券代码：605116 证券简称：奥锐特 公告编号：2025-029 债券代码：111021 债券简称：奥锐转债 关于公司2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号） 和上海证券交易所印发的《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作（2023 年 12 月修订）》（上证发〔2023〕193 号）的规定及奥锐特 药业股份有限公司（以下简称"公司"或"本公司"）《募集资金使用管理制 度》的相关规定，公司现将 2024 年度募集资金存放与实际使用情况专项说明 如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意奥锐特药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2024〕924 号），本公 司由主承销 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—3 页 奥锐特公司管理层的责任是提供真实、合法、完整的相关资料，按照《上市 公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《上海证券交易所上市公司自律监管指南第 2 号——业务 办理（2024 年 5 月修订）》（上证函〔2024〕1476 号）的规定编制汇总表，并 保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 第 1 页 共 3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕7475 号 奥锐特药业股份有限公司全体股东： 我们接受委托，审计了奥锐特药业股份有限公司（以下简称奥锐特公司）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变 动表，以及财务报表附注，并出具了审计报告。在此基础上，我 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-027 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 24 日，奥锐特药业股份有限公司（以下简称"公司"）召开第 三届董事会第十三次会议，审议通过了《关于公司及子公司向银行及其他融资机 构申请综合授信额度的议案》，现将相关内容公告如下： 为满足公司业务发展需要及日常生产经营需要，降低融资成本，提高资金营 运能力。结合公司实际情况及发展规划，公司及子公司拟向包括但不限于银行等 金融机构申请总额不超过 50,000 万元人民币授信额度。授信额度有效期为自审 议本议案的董事会决议通过之日起至下一年度审议综合授信额度的董事会决议 通过之日。在授信期限内，授信额度可循环使用，无需公司另行审议。 公司及子公司申请的综合授信，可用于办理包括但不限于短期流动资金贷 款、长期借款、银行承兑汇票、商业承兑汇票、保函、信用证、抵押/质押贷款 等。上述授信额度不等于公司及子公司实际融资金额，实际授信 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-025 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于使用闲置自有资金进行委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 委托理财受托方: 商业银行及具有合法经营资格的金融机构。 本次委托理财金额:单日最高余额不超过人民币 50,000 万元，在上述额 度内，资金可以滚动使用。 履行的审议程序:公司于 2025 年 4 月 24 日召开的第三届董事会第十三次 会议及第三届监事会第十一次会议分别审议通过了《关于公司使用闲置自有资金 进行委托理财的议案》，同意公司在不影响正常经营活动的情况下，使用单日最 高余额不超过 50,000 万元的闲置自有资金进行委托理财，在上述额度内，资金 可以滚动使用。 公司及子公司将本着严格控制风险的原则选择风险可控的委托理财产 品，但金融市场波动较大，不排除预期收益受到市场风险、政策风险、流动性风 险、不可抗力风险等风险因素的影响。 一、本次委托理财概况 （一）委托理财目的 委托理 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-026 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于对外担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）本次担保事项履行的内部决策程序 2025年4月24日，奥锐特药业股份有限公司（以下简称"公司"）第三届董 事会第十三次会议审议通过了《关于对外担保额度预计的议案》。表决结果为： 9票同意，0 票反对，0 票弃权。 根据上海证券交易所的相关规定，本次担保无需提交股东大会审议。 （二）担保预计基本情况 | | | 被担保人名称：公司全资子公司扬州奥锐特药业有限公司（以下简称 "扬州奥锐特"） 本次预计担保额度：累计不超过 30,000 万元（包括已发生且延续至 2025 年的担保） 本次担保是否有反担保：无 对外担保逾期的累计数量：无 | 被担保方 | 扬州奥锐特 | | --- | --- | | 担保方持股比例 | 100% | | 被担保方最近一期资产负债率（2025年3月3 ...

关于奥锐特药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 委托单位：奥锐特药业股份有限公司 审计单位：天健会计师事务所（特殊普通合伙） 联系电话：0571-89722900 目 录 | | | 二、非经营性资金占用及其他关联资金往来情况汇总裁 ………… 第 3-3页 ini 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://www.find.gov.cn）" "打 " "创" 目 录 1、 专项审计报告 2、 附表 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕7475 号 奥锐特药业股份有限公司全体股东: 我们挨受委托,审计了奥锐特药业股份有限公司(以下简称奥锐特公司)2024 年度财务报表,包括 2024年12月31日的合并及母公司资产负债表,2024年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变 动表,以及财务报表附注,并出具了审计报告。在此基础上,我们审计了后附的 奥 锐特公司管理层编制的 2024 年度《非经营性资金占用及其他关联资金往来情 况汇总表》(以下简称汇总表)。 一、对报告使用者 ...

公司代码：605116 公司简称：奥锐特 奥锐特药业股份有限公司 2024年度内部控制评价报告 奥锐特药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部 ...